MX2021004215A - Combinaciones de inhibidores de la replicación del virus de la gripe. - Google Patents

Combinaciones de inhibidores de la replicación del virus de la gripe.

Info

Publication number
MX2021004215A
MX2021004215A MX2021004215A MX2021004215A MX2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A
Authority
MX
Mexico
Prior art keywords
replication
combinations
inhibitors
influenza virus
influenza
Prior art date
Application number
MX2021004215A
Other languages
English (en)
Spanish (es)
Inventor
Irina C Jacobson
Biing Yuan Lin
Sam Sk Lee
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of MX2021004215A publication Critical patent/MX2021004215A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021004215A 2018-10-17 2019-10-17 Combinaciones de inhibidores de la replicación del virus de la gripe. MX2021004215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746884P 2018-10-17 2018-10-17
PCT/US2019/056632 WO2020081751A1 (en) 2018-10-17 2019-10-17 Combinations of inhibitors of influenza virus replication

Publications (1)

Publication Number Publication Date
MX2021004215A true MX2021004215A (es) 2021-07-15

Family

ID=68503202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004215A MX2021004215A (es) 2018-10-17 2019-10-17 Combinaciones de inhibidores de la replicación del virus de la gripe.

Country Status (17)

Country Link
US (1) US12233066B2 (https=)
EP (1) EP3866778B1 (https=)
JP (1) JP7577652B2 (https=)
KR (1) KR102890706B1 (https=)
CN (1) CN112969457B (https=)
AU (1) AU2019361038B2 (https=)
BR (1) BR112021007275A2 (https=)
CA (1) CA3115823A1 (https=)
DK (1) DK3866778T3 (https=)
ES (1) ES2939148T3 (https=)
FI (1) FI3866778T3 (https=)
IL (1) IL282018B2 (https=)
MX (1) MX2021004215A (https=)
PL (1) PL3866778T3 (https=)
PT (1) PT3866778T (https=)
TW (1) TWI829785B (https=)
WO (1) WO2020081751A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158020A1 (en) * 2020-05-23 2023-05-25 Alexandre Vasilievich Ivaschenko Method for treating RNA viral infections, including COVID-19 (SARS-CoV-2)
WO2022074630A1 (en) * 2020-10-09 2022-04-14 Auxilla Pharmaceuticals And Research Llp Liquid oral suspension of favipiravir
CN113413365B (zh) * 2021-07-30 2022-11-22 合肥医工医药股份有限公司 一种稳定的法维拉韦口服溶液制剂及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
CA2070823C (en) 1989-12-05 1999-01-12 William H. Ii Frey Neurologic agents for nasal administration to the brain
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
AU6526100A (en) 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002013897A2 (en) 2000-08-14 2002-02-21 Advanced Inhalation Research, Inc. Inhalation device and method
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ,インコーポレイテッド 持続放出特性を有する吸入用粒子
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
AU2002352836B2 (en) 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
EP1673123A2 (en) 2003-09-05 2006-06-28 Kurve Technology, Inc. Integrated nebulizer and particle dispersing chamber for delivery of medicament
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
CN108276401B (zh) * 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (en) * 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
TWI778052B (zh) * 2017-04-24 2022-09-21 美商共結晶製藥公司 流感病毒複製之抑制劑

Also Published As

Publication number Publication date
AU2019361038B2 (en) 2025-07-03
KR102890706B1 (ko) 2025-11-24
FI3866778T3 (fi) 2023-03-21
EP3866778B1 (en) 2022-11-30
EP3866778A1 (en) 2021-08-25
KR20210080413A (ko) 2021-06-30
JP7577652B2 (ja) 2024-11-05
IL282018B1 (en) 2025-02-01
IL282018B2 (en) 2025-06-01
CA3115823A1 (en) 2020-04-23
US20210353629A1 (en) 2021-11-18
CN112969457B (zh) 2025-10-28
DK3866778T3 (da) 2023-02-20
TW202024090A (zh) 2020-07-01
AU2019361038A1 (en) 2021-05-13
US12233066B2 (en) 2025-02-25
WO2020081751A1 (en) 2020-04-23
IL282018A (en) 2021-05-31
TWI829785B (zh) 2024-01-21
BR112021007275A2 (pt) 2021-07-20
CN112969457A (zh) 2021-06-15
JP2022505183A (ja) 2022-01-14
PT3866778T (pt) 2023-02-28
PL3866778T3 (pl) 2023-03-27
ES2939148T3 (es) 2023-04-19

Similar Documents

Publication Publication Date Title
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
MX387115B (es) Métodos para tratar la influenza.
ECSP17073878A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
EA201691931A1 (ru) 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
CR20180213A (es) Derivados de indol mono -o- disustituidos como inhibidores de la replicación viral del dengue
EA201890723A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX383931B (es) Compuestos de aza-piridona y usos de estos.
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
EA201990064A1 (ru) Противомалярийные композиции и варианты их применения
UA120066C2 (uk) Застосування таурину для профілактики і/або лікування захворювань, викликаних вірусами роду коронавірусів і/або роду ротавірусів
CO2020003134A2 (es) Moduladores de la expresión de enac